{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:08:30Z","timestamp":1770836910394,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T00:00:00Z","timestamp":1346803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biotechnology Journal"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This report highlights the potential of measurement, monitoring, modeling and control (M<jats:sup>3<\/jats:sup>C) methodologies in animal and human cell culture technology. In particular, state\u2010of\u2010the\u2010art of M<jats:sup>3<\/jats:sup>C technologies and their industrial relevance of existing technology are addressed. It is a summary of an expert panel discussion between biotechnologists and biochemical engineers with both academic and industrial backgrounds. The latest ascents in M<jats:sup>3<\/jats:sup>C are discussed from a cell culture perspective for industrial process development and production needs. The report concludes with a set of recommendations for targeting M<jats:sup>3<\/jats:sup>C research toward the industrial interests. These include issues of importance for biotherapeutics production, miniaturization of measurement techniques and modeling methods.<\/jats:p>","DOI":"10.1002\/biot.201200226","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T06:35:39Z","timestamp":1346826939000},"page":"1522-1529","source":"Crossref","is-referenced-by-count":46,"title":["How can measurement, monitoring, modeling and control advance cell culture in industrial biotechnology?"],"prefix":"10.1002","volume":"7","author":[{"given":"Manuel J. T.","family":"Carrondo","sequence":"first","affiliation":[]},{"given":"Paula M.","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Carinhas","sequence":"additional","affiliation":[]},{"given":"Jarka","family":"Glassey","sequence":"additional","affiliation":[]},{"given":"Friedemann","family":"Hesse","sequence":"additional","affiliation":[]},{"given":"Otto\u2010Wilhelm","family":"Merten","sequence":"additional","affiliation":[]},{"given":"Martina","family":"Micheletti","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Noll","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Udo","family":"Reichl","sequence":"additional","affiliation":[]},{"given":"Arne","family":"Staby","sequence":"additional","affiliation":[]},{"given":"Ana P.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Henry","family":"Weichert","sequence":"additional","affiliation":[]},{"given":"Carl\u2010Fredrik","family":"Mandenius","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2012,9,5]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"Sch\u00fcgerl K. Bioreaction Engineering Bioprocess Monitoring Vol. 3 John Wiley & Sons Chichester UK 1997."},{"key":"e_1_2_9_3_2","first-page":"1","article-title":"Instrumentation of biotechnological processes.","volume":"66","author":"Sonnleitner B.","year":"1999","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00449-004-0383-z"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2009.05.003"},{"key":"e_1_2_9_6_2","unstructured":"United States Federal Food and Drug Administration (USA) Guidance for Industry Process Analytical Technology FDA 2004."},{"key":"e_1_2_9_7_2","unstructured":"European Medicines Agency EMA\u2010FDA pilot program for parallel assessment of Quality by Design applications. Document EMA\/172347\/2011 2011."},{"key":"e_1_2_9_8_2","unstructured":"International conference on Harmonization (ICH) Document ICH Q1\u2013Q11 2005\u20132011. Available at www.ich.org."},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201000356"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200800333"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026104"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2010.07.020"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200600010"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2011.09.014"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-8-45"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2012.03.003"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.076"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-4-61"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-010-0466-7"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.23229"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/026119291103900210"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-005-3587-4"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-011-0686-5"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2005.06.031"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.23131"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-010-2743-8"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201100506"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-5-34"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-30"},{"key":"e_1_2_9_30_2","doi-asserted-by":"crossref","unstructured":"Rathore A. S. Mhatre R. (Eds.) Quality by Design for Biopharmaceuticals: Principles and Case Studies Wiley and Sons Inc. New York 2009.","DOI":"10.1002\/9780470466315"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ceat.201100282"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.09.001"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2008.06.009"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ceat.200800457"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2006.12.023"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.1536"}],"container-title":["Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbiot.201200226","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/biot.201200226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:48:20Z","timestamp":1759924100000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/biot.201200226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,5]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1002\/biot.201200226"],"URL":"https:\/\/doi.org\/10.1002\/biot.201200226","archive":["Portico"],"relation":{},"ISSN":["1860-6768","1860-7314"],"issn-type":[{"value":"1860-6768","type":"print"},{"value":"1860-7314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,5]]}}}